DPZ Signs License Agreement with Biogen Idec

22-Feb-2011 - Germany

The German Primate Center (DPZ) and its technology transfer partner Ascenion announced the signing of a license agreement providing Biogen Idec with exclusive, worldwide rights to a patent portfolio directed to a recombinant virus-like particle (VLP) containing VP1 protein for the detection of antibodies to JC virus (JCV). The license provides authorization for Biogen Idec’s use of this VLP in a test in the context of multiple sclerosis (MS) and, optionally, certain other indications. In return, the DPZ receives undisclosed upfront and milestone payments as well as royalties related to the VLP’s use.

DPZ’s patents relating to JCV cover certain diagnostic and therapeutic applications of recombinant VP1.These proteins self-assemble into VLPs with the typical JCV morphology and can be used as highly specific antigens for detecting anti-JCV antibodies in human serum or blood.

”The DPZ has single-mindedly built and sustained its IP portfolio on JCV over many years,” said Michael Lankeit, Administrative Director of the DPZ. “We are delighted to partner with Biogen Idec on this important initiative.”

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous